Arovella Therapeutics Ltd at TechKnow Investor Conference - Melbourne Transcript
Great. Thanks very much, Christy, and thanks very much to the organizers for putting the events, of course, big thank you to everybody for taking the time to listen in today, we're delighted to have you here. And so yes, that's exactly what we're talking about Arovella Therapeutics. For those of you that don't know. I said ticker is ALI. and we are a biotechnology company focused on the battle against cancer. I will be making forward-looking statements, so please do take note of the disclaimers.
Now I'd like to start with the highlights of the Company and what we're working on. We determine the invariant natural killer T cell platform, which is a mouthful, and I'll unpack what that means in a moment. And for short, we call it iNKT cells, and we're using that to develop initially treatments for blood cancers.
But as Christy just mentioned, also looking to tactical a range of solid tumors as we build out from behind. So our lead product is ALA-101 that's going after very specific form of blood cancer leukemia or lymphoma. That
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |